Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Asciminib: First Approval
Emma D. Deeks
Drugs (2022) Vol. 82, Iss. 2, pp. 219-226
Closed Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Robert Roskoski
Pharmacological Research (2022) Vol. 187, pp. 106552-106552
Open Access | Times Cited: 242
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Yang Yang, Shuo Li, Yujiao Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 144
Fluorine-containing drugs approved by the FDA in 2021
Jingrui He, Ziyi Li, Gagan Dhawan, et al.
Chinese Chemical Letters (2022) Vol. 34, Iss. 1, pp. 107578-107578
Closed Access | Times Cited: 114
Protein lipidation in health and disease: molecular basis, physiological function and pathological implication
Yuan Yuan, Peiyuan Li, Jianghui Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 26
Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 21
The Role of Small Molecules Containing Fluorine Atoms in Medicine and Imaging Applications
Emily Henary, Stefanie Casa, Tyler L. Dost, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 281-281
Open Access | Times Cited: 20
Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
Kun Pang, Wei Wang, Jiaxin Qin, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 68
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Robert Roskoski
Pharmacological Research (2022) Vol. 178, pp. 106156-106156
Closed Access | Times Cited: 46
The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine
Qian Wang, Jianlin Han, Alexander E. Sorochinsky, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 8, pp. 999-999
Open Access | Times Cited: 43
Targeting Gatekeeper Mutations for Kinase Drug Discovery
Yang Zhou, Shuang Xiang, Fang Yang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 23, pp. 15540-15558
Closed Access | Times Cited: 39
Applications and prospects of cryo-EM in drug discovery
Kongfu Zhu, Chuang Yuan, Yongming Du, et al.
Military Medical Research (2023) Vol. 10, Iss. 1
Open Access | Times Cited: 35
Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy
Fengling Wang, Xue Zhang, Yanyan Wang, et al.
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 5, pp. 543-559
Open Access | Times Cited: 34
Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers
Zhi Xu, Yafei Zhuang, Qingtai Chen
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115495-115495
Closed Access | Times Cited: 28
New drug approvals for 2021: Synthesis and clinical applications
Shuo Yuan, Dan-Shu Wang, Hui Liu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114898-114898
Closed Access | Times Cited: 32
Synthetic Approaches to the New Drugs Approved During 2021
Emma L. McInturff, Scott P. France, Carolyn A. Leverett, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10150-10201
Closed Access | Times Cited: 15
A decade of pyridine containing heterocycles in the approved USFDA drugs: A medicinal chemistry-based analysis
Ashish Ranjan Dwivedi, Shivani Jaiswal, Deepak Kukkar, et al.
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 5
Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
Yanping Li, Ruoqiu Fu, Tingting Jiang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 21
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults
Khalil Saleh, Alexis Fernández, Florence Pasquier
Cancers (2022) Vol. 14, Iss. 7, pp. 1805-1805
Open Access | Times Cited: 21
Intestinal Metabolism of Diclofenac by Polymorphic UGT2B17 Correlates with its Highly Variable Pharmacokinetics and Safety across Populations
Deepak Ahire, Scott Heyward, Bhagwat Prasad
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 1, pp. 161-172
Open Access | Times Cited: 11
A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
Rasha Kaddoura, Wafer Dabdoob, Khalid Ahmed, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 11
Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor
Haixia Liu, Qianglong Mi, Xinyu Ding, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114810-114810
Closed Access | Times Cited: 19
Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors
Dou Dou, Jie Wang, Yunjin Qiao, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114856-114856
Closed Access | Times Cited: 18
The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia
Zhuo Qian, Yi‐Ru Bai, Wenjuan Zhou, et al.
Bioorganic Chemistry (2025) Vol. 156, pp. 108189-108189
Closed Access
Non-enzymatic protein targeting agents as a promising strategy for cancer treatment
M. Ambrose, Jin-Hyung Lee, Aleem Syed, et al.
Frontiers in Drug Discovery (2025) Vol. 5
Open Access
Isolation of Allosteric Tryptase Inhibitor from Methanol Extract of Rhubarb and Enhancement of Its Tryptase Inhibitory Activity by Compounds That Were Screened by In Silico Screening
Hidetoshi Fujii, Moeno Ito, K. Nishioka, et al.
Molecules (2025) Vol. 30, Iss. 6, pp. 1341-1341
Closed Access
Page 1 - Next Page

Scroll to top